Navigation Links
OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
Date:10/22/2010

n, also referred to as OGX-011.  Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer.  The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 has entered Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.  More information about OncoGenex is available at www.oncogenex.com.

More information about OncoGenex is available at www.oncogenex.com. OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, OncoGenex' estimate of the net proceeds of the public offering and the anticipated use of such proceeds.  All statements other than statements of historical fact are statements that could be deemed forward-looking statements.  These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the ability to manage successfully and complete the public offering, the economic and/or market conditions generally, risks relating to OncoGenex' operations and financial performance and the factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Quarterly Report on Form 10-Q for second fiscal quarter of 2010 and the preliminary prospectus supplement to be filed with the SEC.  The Company undertakes no obligation to update the forward-looking statements contained h
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
2. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
3. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
4. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
5. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
6. OncoGenex Reports Second Quarter Financial Results
7. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
9. OncoGenex Reports First Quarter Financial Results
10. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
11. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Spartan Bioscience announced today that Health Canada ... It detects CYP2C19 genetic mutations in less than 60 ... RX CYP2C19 System is the first near-patient DNA test ... Due to the system’s ease of use, Health Canada ... professionals such as doctors, nurses, pharmacists, and laboratory technicians, ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success ... of its fleet of high volume High Pressure Processing (HPP) ... we return to PackExpo this year, which is where we ... said Jeff Williams, CEO at Avure. “Sales of the new ... be meeting the challenges of market demand for higher throughput. ...
(Date:10/30/2014)... CARLSBAD, Calif. , Oct. 30, 2014 Isis ... antisense therapeutics, today announced that management will present a company ... 2014 at 8:30 a.m. ET in Boston, MA. ... will be available on the "Investors & Media" section of ... available on the Isis website within 48 hours and will ...
(Date:10/30/2014)... 2014  Regado Biosciences, Inc. (Nasdaq: RGDO ... call and live audio webcast on Thursday, November 6, ... quarter 2014 financial results. Interested participants and ... 347-1165 for domestic callers or (412) 902-4276 for international ... the investor relations section of the Regado website at ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2
... news item is out of step with public opinion in ... state of Wisconsin grants $1 million and loans another $1 ... UW-Madison researcher so renowned that the words "Nobel Prize" practically ... drug discovery. , ,• The National Institutes of Health, the ...
... records have led to some adoption of the technology but ... ,Then Hurricane Katrina slammed into the Gulf Coast, destroying countless ... ,Katrina, and her followup Rita, may not only have changed ... focus of debate on electronic healthcare records. It is becoming ...
... -- Research scientist Seth Dobrin, Ph.D., has been named ... Genotyping Service of the Marshfield Clinic Research Foundation. , ,He ... to problems of mental health and development of new genetic ... discoveries he made earlier in his career as well as ...
Cached Biology Technology:Stem cell bank announcement validates quality of Wisconsin research 2Stem cell bank announcement validates quality of Wisconsin research 3Katrina's destruction likely to speed up electronic healthcare records adoption 2Katrina's destruction likely to speed up electronic healthcare records adoption 3Katrina's destruction likely to speed up electronic healthcare records adoption 4
(Date:10/28/2014)... differences in moving activity in a novel environment ... angling, according to an experimental study completed at ... Game and Fisheries Research Institute. The study used ... and authentic angling trials to analyse if behaviours ... reared in traditional and enriched hatchery rearing environments. ...
(Date:10/28/2014)... and citrus fruits and juices are associated with a ... research from the University of East Anglia (UEA). ... foods containing flavonols and flavanones (both subclasses of dietary ... cancer, the fifth-leading cause of cancer death among women. ... of 171,940 women aged between 25 and 55 for ...
(Date:10/27/2014)... are an indigenous species of the West Antarctic Peninsula ... Earth. Since 1950, the average annual temperature in the ... and 6 degrees Celsius during winter. , As ... dry, polar system to a warmer, sub-polar system with ... a connection between local weather conditions and the weight ...
Breaking Biology News(10 mins):Fish 'personality' linked to vulnerability to angling 2Tea and citrus products could lower ovarian cancer risk, new UEA research finds 2University of Delaware study connects penguin chick weights to local weather conditions 2University of Delaware study connects penguin chick weights to local weather conditions 3
... they used fluorescent molecules to "tag" DNA and monitor a ... rearranging genetic material in some types of cells. ... light on how DNA loops form, but also might be ... shuffle genetic material, such as HIV. Until now, scientists ...
... more DNA regions linked to type 2 diabetes have been ... to over 60. The study provides a fuller picture ... with some clear patterns emerging. The international team, ... Institute of Harvard and MIT, and the University of Michigan, ...
... affordable and accessible, we need to pay more attention to ... and the fact that we don,t yet understand what ... Hastings Center Report . The authors are current or former ... Most analyses of the ethical issues raised by whole ...
Cached Biology News:Scientists use light to 'tag and track' genetic processes 210 new diabetes gene links offer picture of biology underlying disease 210 new diabetes gene links offer picture of biology underlying disease 3Prenatal whole genome sequencing: Just because we can, should we? 2Prenatal whole genome sequencing: Just because we can, should we? 3
Mouse monoclonal antibody raised against a partial recombinant FBXO24. NCBI Entrez Gene ID = FBXO24...
Mouse monoclonal antibody raised against a partial recombinant CALCOCO2. NCBI Entrez Gene ID = CALCOCO2...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
...
Biology Products: